Positive impact of genetic counseling assistants on genetic counseling efficiency, patient volume, and cost in a cancer genetics clinic

[1]  S. Friedman,et al.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  J. Vadgama,et al.  PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers , 2019, Journal of clinical medicine.

[3]  A. Trepanier,et al.  Genetic counselor workflow study: The times are they a‐changin’? , 2018, Journal of genetic counseling.

[4]  R. Bennett,et al.  Projecting the Supply and Demand for Certified Genetic Counselors: a Workforce Study , 2018, Journal of Genetic Counseling.

[5]  M. Markman.  Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer , 2018, Women's health.

[6]  Sara Pirzadeh-Miller,et al.  Genetic Counseling Assistants: an Integral Piece of the Evolving Genetic Counseling Service Delivery Model , 2017, Journal of Genetic Counseling.

[7]  M. McAllister,et al.  Standards for the Reporting of Genetic Counseling Interventions in Research and Other Studies (GCIRS): an NSGC Task Force Report , 2017, Journal of Genetic Counseling.

[8]  L. Schofield,et al.  A Retrospective Exploration of the Impact of the ‘Angelina Jolie Effect’ on the Single State-Wide Familial Cancer Program in Perth, Western Australia , 2017, Journal of Genetic Counseling.

[9]  Stephanie A Cohen,et al.  A collaborative approach to cancer risk assessment services using genetic counselor extenders in a multi-system community hospital , 2016, Breast Cancer Research and Treatment.

[10]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[11]  Diana M Eccles,et al.  The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services , 2014, Breast Cancer Research.

[12]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[13]  A. Kesselheim,et al.  Gene patenting--the Supreme Court finally speaks. , 2013, The New England journal of medicine.

[14]  Julie O. Culver,et al.  Essential Elements of Genetic Cancer Risk Assessment, Counseling, and Testing: Updated Recommendations of the National Society of Genetic Counselors , 2012, Journal of Genetic Counseling.

[15]  M. Robson,et al.  American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Parmigiani,et al.  Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomothearapy , 2009, Radiation oncology.

[17]  John Fox,et al.  Applied Regression Analysis and Generalized Linear Models , 2008 .

[18]  Giovanni Parmigiani,et al.  BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Timothy J. Robinson,et al.  Multilevel Analysis: Techniques and Applications , 2002 .

[20]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[21]  J. Hox.  Multilevel analysis: Techniques and applications, 2nd ed. , 2010 .

[22]  J. Stockman,et al.  Prediction of Germline Mutations and Cancer Risk in the Lynch Syndrome , 2008 .

[23]  J. Hox,et al.  Sufficient Sample Sizes for Multilevel Modeling , 2005 .

[24]  G. A. Marcoulides,et al.  Multilevel Analysis Techniques and Applications , 2002 .